Randomised Evaluation of COVID-19 Therapy

• Status: Recruiting
• Trial end date: 2031-12-01
• Target enrollment: 0
• Participant gender: All

Summary

RECOVERY is a randomised trial investigating whether treatment with Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Synthetic neutralizing antibodies (REGN-COV2), Tocilizumab, Aspirin, Baricitinib, Infliximab, Empagliflozin or Anakinra (children only) prevents death in patients with COVID-19.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oxford
• Collaborators: Bill and Melinda Gates Foundation; Department for International Development, United Kingdom; Health Data Research UK; Medical Research Council Population Health Research Unit; National Institute for Health Research, United Kingdom; NIHR Clinical Trials Unit Support Funding; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections; UK Research and Innovation; Wellcome
• Treatments: Antibodies; Aspirin; Azithromycin; Colchicine; Dimethyl Fumarate; Empagliflozin; Hydroxychloroquine; Immunoglobulins; Immunoglobulins, Intravenous; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• (i) Hospitalised

• (ii) SARS-CoV-2 infection (clinically suspected or laboratory confirmed)

• (iii) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial

Exclusion Criteria:

• If the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms (see Protocol Appendix 2; section 8.2 and Appendix 3; section 8.3 for children) or that the patient should definitely be receiving one of the active drug treatment arms then that arm will not be available for randomisation for that patient. For patients who lack capacity, an advanced directive or behaviour that clearly indicates that they would not wish to participate in the trial would be considered sufficient reason to exclude them from the trial.